Skip to main content

Table 5 Peripheral blood markers to predict irAEs induced by nivolumab treatment

From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

 

AUC

95% CI

P value

CA19-9

0.692

0.560–0.823

0.022

P-CRP

0.680

0.547–0.822

0.032

CRP

0.656

0.512–0.800

0.063

CAR

0.625

0.472–0.779

0.138

Platelet

0.583

0.420–0.745

0.322

CEA

0.569

0.403–0.735

0.423

PLR

0.553

0.391–0.715

0.527

NLR

0.552

0.399–0.704

0.537

LDH

0.547

0.396–0.697

0.576

PNI

0.470

0.315–0.625

0.724

Albumin

0.442

0.270–0.613

0.488

  1. irAEs Immune-related adverse events AUC, Area under the curve CI, Confidence internal CA 19–9, Carbohydrate antigen 19–9 P-CRP, Platelet count × serum C-reactive protein level multiplier value CRP, C-reactive protein CAR, C-reactive protein-to-albumin ratio CEA, Carcinoembryonic antigen PLR, Platelet-to-lymphocyte ratio NLR, Neutrophil-to-lymphocyte ratio LDH, Lactate dehydrogenase PNI, Prognostic nutritional index
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us